A Single-Center, Open-Label, Single-Arm, Fixed-Sequence Phase I Clinical Study to Evaluate the Effect of Multiple Doses of Rifampin or Itraconazole on the Pharmacokinetics of VCT220 in Healthy Subjects

Registration

Registration

NCT07056842

Study type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Phase

PHASE1

Masking

NONE

Status

COMPLETED

Enrollment

32

Start

2025-07-20

Primary completion

2025-08-11

Lead sponsor

Vincentage Pharma Co., Ltd

Conditions

Obesity &Amp; Overweight

Interventions

DRUG:Rifampin + VCT220; DRUG:Itraconazole + VCT220

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• Area under plasma concentration-time curve from time zero to infinity (AUC) for VCT220. [1 hour pre-dose on D1 and D11, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose]
• Area under plasma concentration-time curve from time zero to infinity (AUC) for VCT220 [1 hour pre-dose on D1 and D12, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose]
• Maximum observed plasma concentration (Cmax) for VCT220 [1 hour pre-dose on D1 and D11, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose]
• Maximum observed plasma concentration (Cmax) for VCT220 [1 hour pre-dose on D1 and D12, and 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h post dose]